Story perspectives

RevMed's Daraxonrasib Shows 76% Tumor Reduction in Cancer Trial

4/10/2026

Summary

Sasse's Cancer Breakthrough

Former U.S. Senator Ben Sasse says he is using RevMed's experimental drug daraxonrasib for Stage 4 pancreatic cancer, reporting a 76% tumor-volume reduction.
RevMed's drug targets RAS mutations common in pancreatic cancer, but its broad activity can cause side effects, including skin issues.
Phase 3 results from the MD Anderson Cancer Center trial in Texas are crucial for FDA approval, and analysts predict RevMed's stock could rise if survival improves.

Summary

Sasse's Treatment Progress

Former Senator Benjamin Sasse has reached Day 99 of treatment with experimental drug daraxonrasib, and his tumor volume fell 76%.
He was diagnosed with Stage 4 pancreatic cancer and given three to four months to live.
Sasse remains optimistic despite side effects such as skin issues and pain.
He expressed concern for his children about the impact of his absence.
He seeks to make his remaining time meaningful through faith.

1 of 2

Sasse's Cancer Breakthrough

Former U.S. Senator Ben Sasse says he is using RevMed's experimental drug daraxonrasib for Stage 4 pancreatic cancer, reporting a 76% tumor-volume reduction.
RevMed's drug targets RAS mutations common in pancreatic cancer, but its broad activity can cause side effects, including skin issues.
Phase 3 results from the MD Anderson Cancer Center trial in Texas are crucial for FDA approval, and analysts predict RevMed's stock could rise if survival improves.

1 / 2